跳至主要内容
临床试验/NCT01544673
NCT01544673已完成1 期

An Open-label, Placebo-controlled Phase 1 Study to Evaluate the Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Male Subjects

Pfizer1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2012年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Pfizer
入组人数
18
试验地点
1
主要终点
Change from baseline in phagocytosis of gram-negative bacteria by neutrophils

研究概览

简要总结

Results from previous studies have been inconclusive and the effect of linezolid on cytokines remains unclear. This study is designed to evaluate the effect of linezolid on the functionality of white blood cells (neutrophils and monocytes) in healthy subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
20 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy male subjects between the ages of 20 and 45 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement and clinical laboratory tests).
  • Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).

排除标准

  • Any condition possibly affecting drug absorption (eg, gastrectomy).
  • Subject who had a bacterial/viral infection within 2 weeks prior to the first dose of study medication.
  • Subjects with current or prior neutropenia (eg, <1.4 x 109 neutrophils /L).

研究组 & 干预措施

Arm A

Active Comparator

干预措施: linezolid (Drug)

Arm B

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Change from baseline in phagocytosis of gram-negative bacteria by neutrophils

时间窗: Baseline, day 4 and day 5

Change from baseline in phagocytosis of gram-negative bacteria by monocytes

时间窗: Baseline, day 4 and day 5

Change from baseline in interleukin-1 receptor antagonist secretion in response to lipopolysaccharide stimulation

时间窗: Baseline, day 4 and day 5

Change from baseline in interleukin-1-beta secretion in response to lipopolysaccharide stimulation

时间窗: Baseline, day 4 and day 5

Change from baseline in interleukin-6 secretion in response to lipopolysaccharide stimulation

时间窗: Baseline, day 4 and day 5

Change from baseline in interleukin-8 secretion in response to lipopolysaccharide stimulation

时间窗: Baseline, day 4 and day 5

Change from baseline in tumor necrosis factor alpha secretion in response to lipopolysaccharide stimulation

时间窗: Baseline, day 4 and day 5

次要结局

  • Linezolid peak concentration on day 4(day 4)
  • Linezolid peak concentration on day 5(day 5)
  • Linezolid trough concentration on day 5(day 5)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验